AIX-EN-PROVENCE, France--(BUSINESS WIRE)--GRAFTYS SA, a company which develops and commercializes biomaterials used in orthopedic surgery, announces that it has recently established an ambitious Post Marketing Surveillance program, in the form of an internationally based registry of patients who have received implants of GRAFTYS® HBS et GRAFTYS® QuickSet. Both of these advanced phosphocalcic cements are highly injectable and resorbable.
This registry will put into practice «evidence-based medicine », which is highly applicable in the medical device industry and is being prioritized by government health authorities throughout the world. The goal is to systematically validate short term and long term clinical results for implantable devices after product launch.
In addition, the registry will document clinical results for recently approved innovative applications of GRAFTYS® HBS et GRAFTYS® QuickSet. Thanks to their high injectability, GRAFTYS cements can be used in numerous applications, such as bone marrow lesions (BML) in the knee, which was recently approved in Europe.
Help employers find you! Check out all the jobs and post your resume.
